Dataset Information

CD229 promotes multiple myeloma cell proliferation by regulating RAS/ERK pathway

ABSTRACT: Flag antibody was used for immunoprecipitation, and cd229-OE partial binding protein was searched by protein spectrum in CD229-OE multiple myeloma cell line, and its interaction was analyzed.

ORGANISM(S): Homo Sapiens

SUBMITTER: Ye Yang

PROVIDER: PXD032177 | iProX | Wed Mar 09 00:00:00 GMT 2022

REPOSITORIES: iProX

ACCESS DATA

Publications

CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation.

Lin Zigen Z Tang Xiaozhu X Cao Yuhao Y Yang Lijin L Jiang Mingmei M Li Xinying X Min Jie J Chen Bing B Yang Ye Y Gu Chunyan C

Aging 20221128 22

Multiple myeloma (MM) is an incurable plasma cell malignancy, while CAR-T therapy offers a new direction for the treatment of MM. Recently, signaling lymphocytic activation molecule family 3 (CD229), a cell surface immune receptor belonging to the signaling lymphocyte activating molecule family (SLAMF), is emerging as a CAR-T therapeutic target in MM. However, a clear role of CD229 in MM remains elusive. In this study, MM patients with elevated CD229 expression achieved poor prognosis by analyzi ...[more]

PMID: 36445333

Similar Datasets

Project description:The paper describes a model of multiple myeloma. Created by COPASI 4.26 (Build 213) This model is described in the article: A mathematical model of cell equilibrium and joint cell formation in multiple myeloma M.A. Koenders, R. Saso Journal of Theoretical Biology 390 (2016) 73–79 Abstract: In Multiple Myeloma Bone Disease healthy bone remodelling is affected by tumour cells by means of paracrine cytokinetic signalling in such a way that osteoclast formation is enhanced and the growth of osteoblast cells inhibited. The participating cytokines are described in the literature. Osteoclast-induced myeloma cell growth is also reported. Based on existing mathematical models for healthy bone remo- delling a three-way equilibrium model is presented for osteoclasts, osteoblasts and myeloma cell populations to describe the progress of the illness in a scenario in which there is a secular increase in the cytokinetic interactive effectiveness of paracrine processes. The equilibrium state for the system is obtained. The paracrine interactive effectiveness is explored by parameter variation and the stable region in the parameter space is identified. Then recently-discovered joint myeloma–osteoclast cells are added to the model to describe the populations inside lytic lesions. It transpires that their presence expands the available parameter space for stable equilibrium, thus permitting a detrimental, larger population of osteoclasts and myeloma cells. A possible relapse mechanism for the illness is explored by letting joint cells dissociate. The mathematics then permits the evaluation of the evolution of the cell populations as a function of time during relapse. To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models . To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

Dataset Information

CD229 promotes multiple myeloma cell proliferation by regulating RAS/ERK pathway

Publications

CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets